HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum

• Zhuming Chen ^[1] ; Muhammad Ali ^[2] ; Zhe Kai ^[1] ; Yang Wang ^[2] ; Chaohui Wang ^[1]
  1. [1] Anhui Medical University

     Anhui Medical University

     China

     
  2. [2] Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, 225001, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 4 (April), 2023, págs. 1011-1016
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Peritoneal metastases (PM) have a poor prognosis in gastric cancer (GC). Cytoreductive surgery (CRS) gives favorable outcomes, but the influence of hyperthermic intraperitoneal chemotherapy (HIPEC) remains contentious. We designed to distinguish results between CRS versus HIPEC-CRS in patients with peritoneal metastases from gastric cancer.

    Materials and methods PubMed, Scopus, Embase and Cochrane library accessed to collect data and language is restricted to English. RevMan 5.4 was used to perform statistical analysis. The outcomes for categorical variables are mentioned in the risk ratio.

    Results Ten trials involving 1367 patients in which 707 were CRS-HIPEC, while 660 CRS. We got significant results in 3rd year survival (P < 0.05), while 1st and 5th years are not statistically significant P > 0.05.

    Conclusion To compare with CRS, CRS-HIPEC has improved survival rate in deprived of further morbidity or mortality.